Knockout-supported antibody specificity checks
Brain and CSF from Mep1b-null mice were used alongside N-terminal and C-terminal antibodies to assess which immunoreactive bands were attributable to meprin-β.
↳ Results, Figs. 1A and 2A
Abstract
The aim of this study is to assess the levels of meprin-β, an alternative β-secretase in the brain and cerebrospinal fluid of subjects suffering Alzheimer's disease. The full-length zymogen and the active species of meprin-β were characterized by immunoblotting and immunoprecipitation using ectodomain N-terminal and C-terminal antibodies. We examined meprin-β changes in extracts from Alzheimer's frontal cortex (n = 13, Braak stages I-II; n = 12, Braak stages III-IV; n = 12, Braak stages V-VI) compared with controls (n = 14), as well as in cerebrospinal fluid samples from Alzheimer's patients (n = 15) or non-Alzheimer's controls (n = 15). Cerebrospinal fluid meprin-β levels were also determined in 19-month old TgF344-AD and wild-type rats. Brain and cerebrospinal fluid from a Mep1b-null mouse served to characterize the specificity of the immunoreactive bands for meprin-β. Human induced pluripotent stem cell (iPSC)-derived neuronal cultures were treated with 2 μM Aβ42 for 24 h. We found that meprin-β is present in human brain extracts and cerebrospinal fluid as several distinct species, attributed to the zymogen and the mature species. These species were absent in brain and cerebrospinal fluid from a Mep1b-null mouse. No fragments of meprin-β were detected in brain extract, either in cerebrospinal fluid. Only the mature forms of meprin-β are increased in frontal cortex extracts (from Braak V-VI), but not the zymogen. The MEP1-B mRNA levels are increased in Braaks III-IV and V-VI compared with controls. The meprin-β species are increased in human neuronal cultures treated with Aβ42. Finally, we demonstrated elevated levels of the mature meprin-β in the cerebrospinal fluid of patients with Alzheimer's disease and in TgF344-AD rats. Our data support a role of meprin-β in Alzheimer's pathology.
Key Claims
Primary findingTentative
Only the mature forms of meprin-β are increased in frontal cortex extracts (from Braak V-VI), but not the zymogen.
Fragile — the claim's weakest requirement is that the effect exists at all. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.
age-imbalanced groups, indirect band assignment, uncorrected comparisons, and inconsistent dispersion reporting limit the late-Braak association
Abstract; Results, Fig. 3B
SecondaryTentative
Finally, we demonstrated elevated levels of the mature meprin-β in the cerebrospinal fluid of patients with Alzheimer's disease and in TgF344-AD rats.
small exploratory comparisons and incompatible SEM–p-value reporting materially limit confidence in the CSF result
Abstract; Results, Figs. 5–6
SecondaryTentative
The meprin-β species are increased in human neuronal cultures treated with Aβ42.
one donor line, supraphysiological treatment, and unreported independent differentiation counts constrain the observed response
Abstract; Results, Fig. 4D
SecondaryTentative
Our data support a role of meprin-β in Alzheimer's pathology.
cross-sectional associations and one acute cell treatment do not identify a pathological role
Abstract; Discussion, Summary
SecondarySupported
The MEP1-B mRNA levels are increased in Braaks III-IV and V-VI compared with controls.
adjacent frontal-cortex tissue showed stage-specific transcript differences, though the exploratory comparisons were not multiplicity-adjusted
Abstract; Results, Fig. 3C
Derived from the full evaluation — not a separate score.
Strengths · Limitations
Strengths
Multiple systems address one question
The study examines human brain, human CSF, iPSC-derived neurons, TgF344-AD rat CSF, and knockout mouse material, providing convergent descriptive observations across matrices and species.
↳ Methods; Results, Figs. 1–6
Key assay limitations are acknowledged
The Discussion states that molecular mass does not directly prove maturation, brain and CSF samples were unpaired, activity was not measured, and independent replication is needed.
↳ Discussion, limitations paragraphs
Limitations
Age confounding affects brain comparison
Controls averaged 55 years, whereas Braak V–VI cases averaged 75 years, and no matched or between-group age-adjusted analysis was reported. Within-group correlations do not isolate disease status from this imbalance.
↳ Methods, Human Brain and CSF Samples; Results, Fig. 3B
Quantitative reporting does not cohere
Values are declared to be means ± SEM, yet examples such as CSF 171 ± 108% with p=0.041 appear incompatible with that convention. Effect magnitudes are also described inconsistently as relative levels or increases.
↳ Methods, Statistical Analysis; Results, Figs. 3B–6B
Species assignment remains indirect
The mature-versus-zymogen interpretation rests principally on an approximately 10 kDa mobility difference without a pro-domain or processed-N-terminus antibody, and enzymatic activity was not measured.
↳ Discussion, meprin-β species interpretation and limitations paragraphs
Nabu Commentary
The study's main contribution is the combination of Braak-stratified brain measurements, human and rat CSF observations, and knockout-supported band characterization. The strongest methodological concern is the approximately 20-year age difference between controls and late-Braak cases without a matched or adjusted analysis, which limits attribution of the brain association to Alzheimer's pathology. Confidence is further reduced by unclear independent replication in the single-donor iPSC arm and by statistical and reagent-reporting inconsistencies. The Discussion acknowledges important uncertainty about molecular-species assignment and absent activity measurements, but it does not integrate the age imbalance into its limitations or final interpretation.
Check another paper
Author Note / Field Feedback
Nabu’s assessment, alongside the field’s view.
Are you an author of this paper?
Dimension breakdown
Study Quality
Limited2.8
Confidence mediumContribution
3.1
The study extends prior brain findings through Braak-stage stratification, CSF analysis, and knockout-supported band characterization. The advance remains incremental and descriptive rather than mechanistic.
Introduction, final two paragraphs; Results, Figs. 1–6
“We report an increase in the mature species of meprin-β in brain and CSF of AD patients”
Methodological Rigour
2.5
Knockout tissue, multiple antibodies, immunoprecipitation, internal blot controls, and total-protein normalization support the assays. The central brain comparison is age-imbalanced without adjustment, while blinding and independent iPSC differentiation counts are unreported.
Methods, Human Brain and CSF Samples; Methods, Western Blot; Results, Figs. 1–5
“Non-demented, control subjects consisted of 14 cases... 55 ± 11 years”
Reporting
3.2
The progression from band characterization to human and model-system comparisons is readily followable. Reagent and figure-caption discrepancies, inconsistent effect reporting, and language claiming a pathological role reduce interpretive precision.
Results, Figs. 1C and 2C; Discussion, Summary
“provide sufficient evidence to support a role of meprin-β in AD pathology”
Positioning
2.8
The paper discusses alternative β-secretases, prior meprin-β findings, band-assignment uncertainty, unpaired brain and CSF samples, and absent activity measurements. It does not incorporate the marked age imbalance into its limitations analysis despite its relevance to the central late-Braak comparison.
Introduction; Methods, Human Brain and CSF Samples; Discussion, limitations paragraphs
“the present finding should be considered conservatively”
Reliability
Caveats4 of 4 checks
Internal CoherenceNoted
Several reporting inconsistencies reduce confidence in the precision of the quantitative and reagent descriptions, although none independently demonstrates invalid central results.
Research ConductClean
Human and animal ethics approvals are declared, and the exploratory, non-preregistered design is disclosed. Questions about the date-like ethics identifier or materials outside the supplied text are assessability gaps rather than demonstrated conduct concerns.
Flags: 1 declared / 5 total
Reference IntegrityClean
48 references in manuscript 48 of 48 checkable references found in an index
Post-Publication RecordClean
No retraction notice found in Retraction Watch.
Last checked: 08 Oct 2026
Sources: Retraction Watch ✓
Readiness
Where this paper’s evidence sits on the path from initial observation to real-world use.
Mechanistic
Human CSF observations and laboratory-model findings provide early biomarker characterization rather than a validated clinical test or intervention. Diagnostic accuracy, prospective performance, and enzymatic activity are not established.
Results, Figs. 4–6; Discussion, limitations paragraphs
AI-generated, human-governed. Something look off? Contact us to request a review.